Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 Blockade

NCT06874257 · clinicaltrials.gov ↗

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

AML (Acute Myelogenous Leukemia)

Interventions

BIOLOGICAL: Laboratory tests and in vitro studies

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna